Volition currently has numerous other ongoing studies on its Nu.
Objective: We evaluated whether telephone-based support could increase the duration of breastfeeding in obese women and, thereby, reduce offspring growth.These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management.These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict.For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations.Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission.
Women dating Hvidovre
A longer duration of breastfeeding may decrease risk of noncommunicable diseases in these infants. Obese women meet obstacles in initiating and maintaining breastfeeding, both exclusively and partially (1–4).The establishment and success of breastfeeding depend on many factors of both biological and psychological origin.Media / Investor Contacts Safe Harbor Statement Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements.Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements.These forward-looking statements relate to the effectiveness of the Company's bodily-fluid-based diagnostic tests as well as the Company's ability to develop and successfully commercialize such test platforms for early detection of cancer.
The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties.
Each sample collected will be sufficient for multiple Nu. Large prospective studies of this quality provide invaluable clinical information.
The partnership with Hvidovre Hospital will support our mission to deliver accurate and cost-effective early stage cancer diagnostics." Volition and Hvidovre Hospital expect to have initial interim results from this study by the end of 2018.
Under the terms of the study, a total of 90,000 blood samples will be collected from 30,000 patients who have tested negative in a national fecal colorectal cancer screening test.
A blood sample will be collected from each patient on three separate occasions at 2-year intervals, and the study will follow his or her progress over time. Q assays detect cancer in samples taken before the definitive diagnosis of colorectal cancer.